Trial reports offer treatment hope for stiff person syndrome
A published trial reports improved walking after an experimental immune-cell treatment, though the small, nonrandomized study leaves important questions unanswered.
The Guardian reports that some people with stiff person syndrome, a rare autoimmune condition affecting the central nervous system, returned to work and hobbies after treatment. The JAMA Neurology study identifies the treatment as mivocabtagene autoleucel, a CAR-T therapy that modifies patients’ immune cells. Its excerpt reports significant improvement in a timed walking test at 16 weeks among 26 treated participants in a nonrandomized trial.
What holds up
- ✓The journal excerpt supports the central claim of promising trial results: the study met its main goal, showing significant improvement in the timed 25-foot walk at 16 weeks.
- ✓Inside Precision Medicine reports that 21 of 26 patients had clinically meaningful walking improvements. The Independent also describes two participants regaining everyday abilities, supporting the broader account of functional gains—not proving that everyone returned to normal life.
What doesn't yet
- ?“Breakthrough” is stronger than the evidence establishes. A small trial without random assignment cannot settle how well this treatment compares with other care, and the supplied excerpts do not provide enough safety information to weigh benefits against harms.
- ?Several reports trace back to the same study and patient accounts, rather than separate tests of the treatment. The Independent and LBC use closely matching accounts and quotations; Kyverna’s announcement is a statement from the trial sponsor, not outside confirmation.
- ?The Guardian’s specific work-and-hobbies claim lacks patient details in its excerpt. USA Today quotes a researcher saying sustained improvement remains a key question; snippets are not a substitute for checking the full study’s follow-up and methods.
Ask before you share
- →How did researchers account for other treatments, natural symptom changes and expectations when measuring improvement?
- →What adverse effects occurred, and how many patients maintained meaningful gains beyond the 16-week assessment?
- →How many participants returned to work or hobbies, and were those outcomes measured systematically or described through selected patient stories?
Sources & original reporting
- [1]The Guardian · Published 9 Nov 2026 · theguardian.com
- [2]Jamanetwork · Published 9 Nov 2026 · jamanetwork.com
- [3]Independent · Published 9 Nov 2026 · independent.co.uk
- [4]Lbc · Published 9 Nov 2026 · lbc.co.uk
- [5]Insideprecisionmedicine · Published 9 Nov 2026 · insideprecisionmedicine.com
- [6]Yahoo · Published 9 Nov 2026 · finance.yahoo.com
- [7]USA Today · Published 9 Nov 2026 · usatoday.com